{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tocilizumab&page=2",
    "query": {
      "intervention": "Tocilizumab",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tocilizumab&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T19:40:49.163Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05869955",
      "title": "A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Idiopathic Inflammatory Myopathy",
        "Systemic Sclerosis",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "CC-97540",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 270,
      "start_date": "2023-09-13",
      "completion_date": "2028-08-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-09-29T19:40:49.163Z",
      "location_count": 25,
      "location_summary": "Aurora, Colorado • Denver, Colorado • Jacksonville, Florida + 16 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05869955"
    },
    {
      "nct_id": "NCT04412772",
      "title": "Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Queen's Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-06-12",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-09-29T19:40:49.163Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04412772"
    },
    {
      "nct_id": "NCT04361552",
      "title": "Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cerebrovascular Accident",
        "Chronic Obstructive Pulmonary Disease",
        "Chronic Renal Failure",
        "Coronary Artery Disease",
        "Diabetes Mellitus",
        "Malignant Neoplasm",
        "SARS Coronavirus 2 Infection"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-04-07",
      "completion_date": "2020-06-02",
      "has_results": false,
      "last_update_posted_date": "2020-06-18",
      "last_synced_at": "2026-09-29T19:40:49.163Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04361552"
    },
    {
      "nct_id": "NCT04529863",
      "title": "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Abatacept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30432,
      "start_date": "2020-08-17",
      "completion_date": "2021-08-31",
      "has_results": false,
      "last_update_posted_date": "2021-11-16",
      "last_synced_at": "2026-09-29T19:40:49.163Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04529863"
    },
    {
      "nct_id": "NCT01163747",
      "title": "A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "tocilizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "23-Valent Pneumococcal Polysaccharide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus Toxoid Adsorbed Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 91,
      "start_date": "2010-09",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2012-12-07",
      "last_synced_at": "2026-09-29T19:40:49.163Z",
      "location_count": 47,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 42 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01163747"
    },
    {
      "nct_id": "NCT07609940",
      "title": "Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma (RRMM)"
      ],
      "interventions": [
        {
          "name": "Linvoseltamab",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-07-15",
      "completion_date": "2028-12-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-09-29T19:40:49.163Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • St. Petersburg, Florida • Baton Rouge, Louisiana + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07609940"
    },
    {
      "nct_id": "NCT04409262",
      "title": "A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19 Pneumonia"
      ],
      "interventions": [
        {
          "name": "Remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 649,
      "start_date": "2020-06-16",
      "completion_date": "2021-03-08",
      "has_results": true,
      "last_update_posted_date": "2022-02-14",
      "last_synced_at": "2026-09-29T19:40:49.163Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Chula Vista, California • Irvine, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04409262"
    },
    {
      "nct_id": "NCT03859388",
      "title": "Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rejection Chronic Renal",
        "Kidney Transplant Rejection"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2019-03-01",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-09-29T19:40:49.163Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03859388"
    },
    {
      "nct_id": "NCT02682823",
      "title": "Tocilizumab Real-Life Human Factors (RLHFs) Validation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "AI-1000 G2",
          "type": "DEVICE"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2016-03-21",
      "completion_date": "2016-07-29",
      "has_results": true,
      "last_update_posted_date": "2019-04-19",
      "last_synced_at": "2026-09-29T19:40:49.163Z",
      "location_count": 8,
      "location_summary": "Mesa, Arizona • Los Alamitos, California • Santa Maria, California + 5 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02682823"
    },
    {
      "nct_id": "NCT07335562",
      "title": "A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "BMS-986353",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2027-02-03",
      "completion_date": "2030-11-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-09-29T19:40:49.163Z",
      "location_count": 17,
      "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 14 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07335562"
    }
  ]
}